

Amendments to the Claims


This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1.-16. (canceled)


17. (New) A method of inhibiting the secretion of IgE-dependent histamine-releasing factor (HRF) in a patient, wherein the method comprises administering to the patient an effective amount of a benzimidazole compound having proton pump inhibitor activity.

18. (New) The method of claim 17, wherein the benzimidazole compound having proton pump inhibitor activity comprises a lipid-soluble weak base of the following formula:



wherein:

P27808.A03



R¹ and R² which may be the same or different each independently represents hydrogen, methoxy, or difluoromethoxy; R³ represents hydrogen or sodium; and R⁴, R⁵ and R⁶, which may be the same or different, each independently represents hydrogen, methyl, methoxy, methoxypropoxy, or trifluoroethoxy.

19. (New) The method of claim 18, wherein the benzimidazole compound comprises one or more of omeprazole, lansoprazole, pantoprazole, rabeprazole, and derivatives and isomers thereof.

20. (New) The method of Claim 19, wherein the method comprises the additional administration of at least one of fenoctimine, oleic acid, catechin, scopadulciol, pentagalloyl glucose, bufalin, bafilomycin and concanamycin.

21. (New) The method of claim 17, wherein the method comprises at least one of prevention and treatment of an allergic disease caused by HRF.

22. (New) The method of claim 21, wherein the allergic disease caused by HRF comprises at least one of asthma, urticaria, anaphylaxis, allergic rhinitis, allergic bronchiectasis, hay fever, atopic dermatitis and malaria.

P27808.A03

23. (New) The method of claim 21, wherein the allergic disease caused by HRF comprises at least one of asthma, urticaria, allergic bronchiectasis, and atopic dermatitis.

24. (New) The method of claim 21, wherein the allergic disease caused by HRF comprises at least one of anaphylaxis, allergic rhinitis, and hay fever.

25. (New) The method of claim 21, wherein the allergic disease caused by HRF comprises malaria.

26. (New) A method of inhibiting the secretion of IgE-dependent histamine-releasing factor (HRF) in a patient, wherein the method comprises administering to the patient an effective amount of at least one compound with proton pump inhibitor activity selected from fenoctimine, oleic acid, catechin, scopadulciol, pentagalloyl glucose, bufalin, bafilomycin and concanamycin.

27. (New) The method of claim 26, wherein the method comprises at least one of prevention and treatment of an allergic disease caused by HRF.

28. (New) The method of claim 27, wherein the allergic disease caused by HRF comprises at least one of asthma, urticaria, allergic bronchiectasis, and atopic dermatitis.

P27808.A03

29. (New) The method of claim 27, wherein the allergic disease caused by HRF comprises at least one of anaphylaxis, allergic rhinitis, and hay fever.

30. (New) The method of claim 27, wherein the allergic disease caused by HRF comprises malaria.

31. (New) The method of claim 18, wherein the method comprises at least one of prevention and treatment of an allergic disease caused by HRF.

32. (New) The method of claim 31, wherein the allergic disease caused by HRF comprises at least one of asthma, urticaria, anaphylaxis, allergic rhinitis, allergic bronchiectasis, hay fever, atopic dermatitis and malaria.

33. (New) The method of claim 19, wherein the method comprises at least one of prevention and treatment of an allergic disease caused by HRF.

34. (New) The method of claim 33, wherein the allergic disease caused by HRF comprises at least one of asthma, urticaria, anaphylaxis, allergic rhinitis, allergic bronchiectasis, hay fever, atopic dermatitis and malaria.

35. (New) The method of claim 20, wherein the method comprises at least one of prevention and treatment of an allergic disease caused by HRF.

P27808.A03

36. (New) The method of claim 35, wherein the allergic disease caused by HRF comprises at least one of asthma, urticaria, anaphylaxis, allergic rhinitis, allergic bronchiectasis, hay fever, atopic dermatitis and malaria.